Cantor Fitzgerald raised the firm’s price target on Apellis (APLS) to $40 from $39 and keeps an Overweight rating on the shares. The Geographic Atrophy market is stabilizing and the launch in C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis is under way, the analyst tells investors in a research note. Cantor believes the Empaveli C3G launch will go well.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis price target lowered to $50 from $52 at Raymond James
- Steady Growth and Future Potential: A Hold Rating for Apellis Pharmaceuticals
- Cautious Outlook on Apellis Pharmaceuticals: Hold Rating Amidst Modest Syfovre Growth and Empaveli Expansion
- Apellis price target raised to $52 from $46 at Citi
- Apellis Pharmaceuticals Reports Q2 2025 Earnings